智通财经APP获悉，中国银河证券发布研报称，看好2026年医药行业投资机会，近期震荡调整后估值已 回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药 (BIC和FIC管线龙头)、创新器械(影像、高值耗材、消费器械等)、医疗AI方向，关注医药消费复苏及独 立第三方ICL。 中国银河证券主要观点如下： 2025创新药大涨投资启示：投资医药"新"资产 2025年医药板块严重分化，3-9月多种因素持续推动创新药板块持续快速大涨，港股创新药表现更为亮 眼。中国创新药研发凭借显著的成本优势与高效的转化能力，在全球医药产业链展示出竞争优势，研发 方向上向FIC、BIC管线升级，从"技术跟随者"逐步成长为"主导参与者"，长期来看将在全球医药创新格 局中地位将持续上升。2025年创新药板块的强势上涨，是政策、产业、需求与全球化共振的结果，从创 新药、到创新器械、医疗AI，医药"新"资产依然是长期投资方向。 2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革 医保支付有望从住院DRGs向门诊APGs拓展，构建全流程闭环管理以提升基金效能;创新药械将获得从 研发加速、审评审 ...

Core Insights - The 2025 Double Eleven shopping festival achieved a record online retail sales of nearly 2.4 trillion yuan, marking a year-on-year growth of over 10% [1] - The beauty category, particularly high-end skincare, showed significant growth driven by trends towards premiumization and rational consumer choices regarding ingredients [1][2] Sales Performance - During Double Eleven, nearly 2,000 beauty, apparel, and sports brands on JD saw their sales double year-on-year, with around 500 subcategories also experiencing similar growth [1] - The growth rates for key beauty subcategories on major e-commerce platforms were led by JD's facial skincare at 12.1%, followed by Douyin at 10.5%, and Taobao and Pinduoduo at 7.3% and 6.2% respectively [1] Consumer Behavior - Over 90% of consumers are now more rational and professional in their selection of beauty products, with 59% choosing products based on their skin type [2] - Familiarity with classic ingredients such as hyaluronic acid, collagen, and niacinamide is high, with recognition rates of 66.8%, 61.9%, and 57.3% respectively [2] Competitive Landscape - In the high-end skincare segment, 93.6% of consumers prefer purchasing from JD due to its reputation for genuine products, delivery speed, after-sales quality, and overall service, surpassing Taobao/Tmall at 43% [5] - JD has become the largest online sales channel for numerous international beauty brands, including Lancôme, La Mer, Helena Rubinstein, Estée Lauder, YSL, Armani, SK-II, Dior, and Givenchy [5] Market Trends - The beauty industry is becoming increasingly competitive, with consumers demanding more rational and precise skincare solutions [5] - Platforms must strengthen their authenticity measures, optimize service chains, and continuously expand their product offerings to meet the evolving beauty consumption demands of consumers [5]

Core Insights - The collagen market is experiencing a downturn, with major brands like Kefu Mei and Juzhi Biotech showing a decline in growth and sales performance [1][5][6] - The market is undergoing a transformation, moving from a focus on consumer beauty products to medical applications, as companies adapt to changing consumer demands and competitive pressures [9][12][13] Market Performance - Kefu Mei's GMV on Douyin dropped to 0.5-0.75 billion yuan from over 1 billion yuan year-on-year [5] - Juzhi Biotech's stock price has fallen by 55.18% since reaching a peak of 85.14 HKD on May 20, 2023 [6][7] - The overall sales performance of collagen brands during the 2025 Double Eleven shopping festival was disappointing compared to previous years [5] Strategic Shifts - Juzhi Biotech is expanding into the B2B market by obtaining medical device registration for a collagen-based product, indicating a strategic shift towards medical applications [7][12] - Companies are increasingly focusing on technological advancements and clinical applications rather than just marketing and branding [10][13] Industry Trends - The collagen industry is moving away from purely cosmetic applications towards medical uses, with a focus on proving efficacy through clinical trials and regulatory approvals [9][12][13] - The competitive landscape is evolving, with companies needing to demonstrate the scientific validity of their products to gain market share [12][13] Innovation and Development - Huaxi Biotech is actively pursuing new patents related to collagen, indicating ongoing investment in research and development [10][11] - Companies like Furuida and Mianmei are also advancing in the medical device space, with new certifications and product developments aimed at surgical applications [12][13]

Group 1 - The company, Dongbao Biological (300239), primarily engages in the research, production, and sales of gelatin, collagen, hollow capsules, and their derivatives [1] - The company has clarified that it does not involve itself in the rare earth sector [1]

Core Insights - The company is developing the Hainan Decheng International Medical and Health Complex project, which is not currently covered by the "Special Medical" policy but benefits from the general policies of the Hainan Free Trade Port [1][2] - The project has been recognized as a major project in Hainan Province for 2025 and has signed a strategic cooperation framework agreement with China General Technology Group's subsidiary, aiming to enhance the company's health service capabilities [2][3] - The company reported a revenue of 278 million yuan for the first nine months of 2025, a year-on-year decrease of 21.71%, and a net loss of 64 million yuan, with losses expanding by 1493.85% compared to the previous year [1] Project Details - The Hainan Decheng International Medical and Health Complex project includes a secondary rehabilitation hospital with a construction area of approximately 15,500 square meters and a total of about 182 beds [2] - The project has a total investment of approximately 489 million yuan and a total construction area of about 71,828 square meters [2] - The project aims to create an international health complex that integrates medical, research, tourism, and wellness services, leveraging high-quality global medical resources [3]

Core Viewpoint - The light industry retail beauty sector is experiencing a weak recovery since 2025, with significant differentiation among sub-sectors and companies due to varying attributes and policy sensitivities. Domestic demand remains weak, while certain segments like trendy toys and beauty products show growth. International trade policies are slowing export growth. Looking ahead to 2026, government policies are expected to support consumption stabilization, but the marginal effects may diminish, leading to differentiated growth across sub-sectors [3]. Beauty and Aesthetic Medicine - The beauty sector is projected to achieve mid-single-digit growth in 2026, driven by domestic demand recovery. Ingredient upgrades and product innovations, particularly with emerging components like collagen and PDRN, are expected to enhance consumer purchasing needs. Competition is intensifying, leading to a concentration of market share among leading brands. The industry is anticipated to exhibit three trends: 1) National brands are moving towards globalization and group development; 2) Channel efficiency and operational capabilities are becoming more critical; 3) Market share is increasingly concentrated among top-performing brands [6]. - The aesthetic medicine sector is expected to see double-digit growth in 2026, supported by increased penetration rates and continuous market education. The supply side is becoming richer, stimulating demand. Two key trends are anticipated: 1) Midstream institutions are focusing on premium products and marketing capabilities; 2) Leading institutions are expanding through enhanced user operations and solutions [7]. Personal Care - The personal care sector is expected to benefit from increased online penetration and the rise of self-care demands, leading to a restructuring of the market. Product structures are anticipated to upgrade towards efficacy and premiumization. The rise of content e-commerce platforms is reshaping consumer access and marketing, providing opportunities for domestic brands to gain market share, particularly in segments like baby care, women's hygiene, and oral care [8]. Commercial New Retail - The retail sector is expected to continue its steady recovery into 2026, characterized by three trends: 1) Consumers are increasingly valuing cost-performance ratios, prompting businesses to focus on differentiated product offerings; 2) The clearance of outdated retail formats is nearing completion, with improved operational efficiency leading to profitability; 3) New consumption trends driven by emotional value are creating demand, supported by innovative product categories and localized operations [10]. Light Industry Manufacturing - The light manufacturing sector is facing weak overall demand but presents structural opportunities. Companies that can leverage industry transformation to develop new business models are expected to thrive. Key opportunities include: 1) Industry transformation driven by technological advancements, particularly in AI applications; 2) Export opportunities as companies enhance resilience through diversified global production and capitalize on improving overseas demand [13][14].

Summary of Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry is experiencing a slowdown in growth, with leading chain institutions and light medical aesthetic models still maintaining growth. Single stores or non-compliant institutions are facing difficulties, and the proportion of channel medical aesthetics is decreasing [1][2][12]. Key Insights and Arguments - Revenue growth for institutions is up 6% year-on-year, with increased customer flow but a decrease in average transaction value (ATV) by approximately 6%. First-tier cities performed particularly well, with an expected annual growth rate of about 10% for chain institutions [1][2][3][4]. - Promotional activities were advanced to September, significantly boosting revenue, with the repurchase rate of existing customers rising to 61% [1][5]. - The pricing strategy varies significantly among products, with low-priced products used for customer acquisition and high-priced products maintaining profit margins. Institutions attract new customers with low initial prices, then revert to original prices for subsequent treatments [1][9][10]. - Regulatory tightening has led to reduced advertising expenditures in traditional channels, shifting focus to customer referrals and internal membership management systems, resulting in decreased marketing costs but improved ROI [1][11]. Market Dynamics - The industry is expected to focus more on profit margins rather than solely on revenue growth, with a projected overall revenue growth of less than 10% by 2026 and a potential further decline in ATV [3][25]. - The customer demographic has shifted, with a 16% year-on-year increase in customer flow in September, and a notable rise in the proportion of returning customers [5]. - High-end products like collagen and hyaluronic acid are expected to see increased procurement, while non-compliant products will be suspended [3][25]. Product Performance - Different price segments are performing well, with significant growth in customer acquisition products such as water light needles and photon rejuvenation [6][8]. - The price of some products has decreased, such as the Ningbo Weimei 4mg product, while high-end products have maintained stable pricing [8][9]. - The market for botulinum toxin has shown stable growth, with annual growth rates exceeding 10% from 2023 to 2025, despite strict regulations limiting advertising [24]. Future Trends - The industry is expected to develop more healthily and sustainably, with a focus on compliance and quality. Non-compliant small institutions may be eliminated due to increased regulatory scrutiny [12][13]. - Mergers and acquisitions are occurring, particularly among traditional institutions that have not adapted to the light medical aesthetic trend [14]. - Institutions prefer self-built stores over acquiring local existing institutions to maintain brand consistency and leverage operational advantages [15]. Conclusion - The medical aesthetic industry is navigating a complex landscape of regulatory changes, shifting consumer preferences, and competitive pressures. Institutions are adapting by refining their marketing strategies, focusing on customer retention, and optimizing product offerings to ensure sustainable growth in a challenging environment [12][30].

Summary of Langzi Co., Ltd. Conference Call Company Overview - **Company**: Langzi Co., Ltd. - **Industry**: Medical Aesthetics and Fashion Retail Key Financial Performance - **Net Profit**: For the first three quarters of 2025, the net profit attributable to shareholders reached 989 million yuan, a year-on-year increase of 366% [2][3] - **Non-recurring Net Profit**: Decreased by 4.1% year-on-year, indicating a need for improvement in profit quality [2][3] - **Operating Cash Flow**: Slight decline observed, reflecting potential operational challenges [2][3] Medical Aesthetics Business - **Revenue Contribution**: Medical aesthetics revenue exceeded 50% of total revenue for the first time, reaching 2.237 billion yuan, a 2.5% increase year-on-year [2][4] - **Gross Margin**: Improved to 55.6%, up 1.8 percentage points year-on-year [2][4] - **Net Profit Contribution**: Decreased by 33.5% year-on-year, indicating challenges in profitability [2][4] - **Revenue Breakdown**: - Milan Fabric Division: 1.159 billion yuan, up 2.2% - Financial Services Division: 393 million yuan, up 9.7% - Hancheng Division: 318 million yuan, up 16% - Wuhan Wuzhou: 146 million yuan, down 9% - Changsha Yamei: 132 million yuan, down 13% - Gao Doctor: 109 million yuan, down 11% [4] Women's Clothing Business - **Revenue**: Approximately 1.407 billion yuan, stable year-on-year [5] - **Gross Margin**: Maintained at around 64% [5] - **Net Profit Contribution**: Increased by 1% year-on-year [5] - **Online Sales Growth**: Significant growth of over 22%, accounting for more than 46% of total women's clothing revenue [5] - **Inventory**: Total inventory at the end of Q3 was approximately 769 million yuan, with a focus on preparing for Q4 [5] Yingdong Division Performance - **Revenue**: Approximately 674 million yuan, a slight decline of 1.6% year-on-year [7] - **Gross Margin**: Decreased by 4.2 percentage points to 61.4% [7][8] - **Net Profit**: Approximately 6.87 million yuan, down 33% [8] Trends in Medical Aesthetics - **Revenue Trends**: Despite a 6% decline in half-year revenue, Q3 showed slight growth of about 2% [9] - **Product Mix Changes**: - Regenerative materials accounted for 22% of revenue, up 5.1 percentage points - Hyaluronic acid decreased to 12.6%, down 1.9 percentage points [9] - **Light Medical Aesthetics**: Increased focus on light medical aesthetics projects, with significant growth in revenue [10] Strategic Considerations - **Pricing Strategy**: Emphasis on providing comprehensive solutions rather than relying solely on product pricing [12] - **Cost Management**: Efforts to reduce customer acquisition costs through channel optimization and content marketing [12] - **M&A Strategy**: Active pursuit of high-quality medical aesthetics targets through external fund acquisitions, with a focus on integration [14][17] Market Environment and Future Outlook - **Market Conditions**: Current market conditions have influenced M&A activities, with many small institutions being acquired for better growth opportunities [15][16] - **Investment Plans**: Positive outlook on future growth, especially in new regions, with ongoing monitoring of potential targets [17] Cost and Supplier Dynamics - **Material Costs**: Decreased by 1.4 percentage points year-on-year, benefiting from strong supplier relationships [19] - **Supplier Power**: Upstream suppliers maintain significant power, particularly in high-end products [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, business segments, strategic initiatives, and market dynamics of Langzi Co., Ltd.

Core Viewpoint - The 2025 Double 11 shopping season reflects a significant shift in consumer behavior towards data-driven and rational consumption, moving away from impulse buying and subjective preferences to a focus on product ingredients and quantifiable benefits [2][4][6]. Consumer Behavior Trends - Nearly 90% of consumers participated in Double 11, with over half making decisive purchases and more than one-third adding desired items to their carts, indicating strong shopping enthusiasm [2]. - In the apparel and beauty sectors, over 75% of consumers plan to purchase autumn and winter clothing, while 47.2% are focused on skincare products, emphasizing a responsible approach to self-care [2][14]. - The rise of "parameter-driven" consumers is evident, as traditional impulsive and subjective buying behaviors decline [2][4]. Ingredient and Parameter Focus - In the beauty sector, nearly 70% of consumers prioritize ingredients like hyaluronic acid and collagen when making purchasing decisions, indicating a strong awareness of product efficacy [3][9]. - In apparel, 74.3% of consumers now check data such as down fill weight and fabric composition, showcasing a shift towards informed decision-making based on product specifications [3][10]. - Platforms are responding by standardizing parameters and enhancing trust through professional selections, with 79.7% of consumers viewing platforms like JD as reliable sources for product specifications [3][19]. E-commerce Platform Dynamics - The shift towards rational consumption has created a positive feedback loop among platforms, brands, and consumers, where brands optimize parameters to meet consumer expectations, and platforms enhance trust through professional curation [4][22]. - Consumers express a need for transparent parameter information, with 36.8% concerned about parameter fraud and 32.8% finding it difficult to obtain accurate information [22][24]. - Leading e-commerce platforms are addressing these challenges by providing clear, certified parameters, which helps consumers make informed choices and reduces the risk of misleading information [23][28]. Seasonal Shopping Insights - During the 2025 Double 11, 65.2% of consumers plan to purchase skincare products, while 61.2% intend to buy winter clothing, reflecting a trend towards "image investment" and self-care [14][18]. - The focus on quality over quantity is evident, with 60.5% prioritizing high-quality materials in winter clothing purchases [18]. - The demand for specific parameters in winter apparel, such as down fill weight and fabric breathability, is high, with 79.7% of consumers considering these factors crucial in their purchasing decisions [12][19].

Core Insights - The collagen market is experiencing significant growth driven by increasing consumer focus on efficacy and ingredients, with two main growth drivers: professional skin care and aesthetic injection applications [1][3] - The collagen market in China is projected to exceed 16 billion yuan at the raw material level and approach 270 billion yuan at the retail level by 2030 [1] - The industry is currently in a phase of policy refinement, accelerated technological iteration, and tight collaboration across the supply chain [1] Industry Structure - The collagen industry has a high degree of integration between raw material supply and end product manufacturing, with upstream suppliers, midstream manufacturers of recombinant collagen, and downstream sales channels [2] - The market is characterized by significant growth potential, high technological barriers, and intense competition [2] End-User Applications - The demand for professional skin care products that combine medical safety and cosmetic efficacy is rapidly increasing, particularly in the aesthetic medicine sector [3] - Applications of collagen products are expanding from traditional moisturizing and nourishing functions to include core roles in aesthetic injection materials [3] Recommended Companies - Companies to watch include: Giant Bio (02367), Jinbo Bio (920982.BJ), Marubi Bio (603983.SH), Huaxi Bio (688363.SH), Fulejia (301371.SZ), Novozymes (688105.SH), Baipusais (301080.SZ), and Betaini (300957.SZ) [4]